Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

CytoMed Therapeutics Limited - Ordinary Shares (NQ:GDTC)

1.930 -0.200 (-9.39%)
Streaming Delayed Price Updated: 3:27 PM EDT, Sep 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about CytoMed Therapeutics Limited - Ordinary Shares

< Previous 1 2 Next >
Update on recent acquisition - CytoMed Therapeutics expands into auto-immune diseases building on its recent cord blood bank acquisition
From CYTOMED THERAPEUTICS LIMITED
Via GlobeNewswire
CytoMed Therapeutics Limited Announces At-the-Market (ATM) Offering Program
From CYTOMED THERAPEUTICS LIMITED
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Intraday Session
 
Via Benzinga
Update On Clinical Trial Milestone - CytoMed Therapeutics Achieves Completion of Dose Level 1 of its ANGELICA TRIAL, and Proceeding to Dose Level 2 in Patients with Advanced Solid Tumors or Haematological Malignancies
From CYTOMED THERAPEUTICS LIMITED
Via GlobeNewswire
CytoMed Therapeutics Reports Full Year Ended December 31, 2024 Financial Results and Provides Clinical and Corporate Updates
From CYTOMED THERAPEUTICS LIMITED
Via GlobeNewswire
CytoMed Therapeutics announces Chairman’s Letter to the Company’s shareholders
From CYTOMED THERAPEUTICS LIMITED
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Via Benzinga
Why Inari Medical Shares Are Trading Higher By 21%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
Singapore-Based CytoMed Therapeutics Stock Dips After SunAct Joins Clinical Trial As Joint Sponsor
CytoMed Therapeutics teams with SunAct for a Phase 1/2 trial on gamma delta T cells in cancer therapy, advancing affordable immunotherapy solutions. 
Via Benzinga
CytoMed Therapeutics signs Business & Research Collaboration Agreement with India’s SunAct Cancer Institute Private Limited to advance use of allogeneic off-the-shelf Gamma Delta T Cells for treatment of solid cancers in a proposed Phase 2 clinical trial
From CYTOMED THERAPEUTICS LIMITED
Via GlobeNewswire
Update on Clinical Milestone - CytoMed Therapeutics Announces First Patient Dosed in its First-in-Human Phase I Clinical Trial of Allogeneic CAR-Gamma Delta T Cell Therapy in Patients with Advanced Solid Tumours or Haematological Malignancies
From CYTOMED THERAPEUTICS LIMITED
Via GlobeNewswire
CytoMed Therapeutics’ first-in-human Phase I ANGELICA clinical trial using its patented donor allogeneic chimeric antigen receptor T cell (CAR-T cell) against blood and solid tumors received co-funding support from the NMRC Clinical Trial Grant
Completion of cash acquisition of licenced cord blood bank expanding CytoMed’s strategy to cord blood-derived biologics through its subsidiary, LongevityBank Pte Ltd 
From CYTOMED THERAPEUTICS LIMITED
Via GlobeNewswire
CytoMed Therapeutics completes cash acquisition of Cord Blood Banking Licence and Assets expanding CytoMed’s strategy to cord blood-derived biologics through subsidiary, LongevityBank
From CYTOMED THERAPEUTICS LIMITED
Via GlobeNewswire
CytoMed Therapeutics Reports Six Months Ended June 30, 2024 Financial Results and Provides Clinical and Corporate Updates
From CYTOMED THERAPEUTICS LIMITED
Via GlobeNewswire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Pre-market stock movers are a hot topic on Friday as we check out all of the stories affecting shares on the last day of trading this week! 
Via InvestorPlace
CytoMed Therapeutics Acquires Cord Blood Banking Licence and Assets to Entrench Its Strategy in Allogeneic, Off-the-shelf Donor-derived Gamma Delta (γδ) T Cells Technology for Solid and Liquid Cancers
Another Patent Granted for CytoMed's Allogeneic Induced Pluripotent Stem Cell (“iPSC”)-derived Hybrid Gamma Delta Natural Killer T (γδ NKT) cells technology 
From CYTOMED THERAPEUTICS LIMITED
Via GlobeNewswire
Navigating the Challenges Facing an Aging Global Population: How CytoMed Seeks to Help Boost Cartilage Regeneration
The global population is rapidly aging. According to the World Population Prospects 2022 published by the United Nations, there were 
Via Spotlight Growth
CytoMed Diversifies into Regenerative Medicine after Research Collaboration with Singapore's Sengkang General Hospital to Test Injectable Umbilical Cord-Derived Mesenchymal Stem Cells for Cartilage Regeneration
Via ACCESSWIRE
CytoMed Therapeutics to Launch Complimentary Cell Banking for Qualified Shareholders for Future Precision Therapies
From CYTOMED THERAPEUTICS LIMITED
Via GlobeNewswire
CytoMed Therapeutics Limited Announces Research Collaboration with Singapore Sengkang General Hospital to Advance Injectable Umbilical Cord-Derived Mesenchymal Stem Cells for Cartilage Diseases and Repair
CytoMed diversifies into regenerative medicine 
From CYTOMED THERAPEUTICS LIMITED
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Via Benzinga
Why Container Store Group Shares Are Trading Lower By Around 23%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Shares of The Container Store Group, Inc. (NYSE: TCS) shares fell sharply during Wednesday’s session following weak quarterly results. 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
 
Via Benzinga
US Stocks Gain; Uber Posts Upbeat Sales
U.S. stocks traded higher this morning, with the Dow Jones gaining around 100 points on Wednesday. Following the market opening Wednesday, the Dow traded up 0.25% to 38,618.79 while the NASDAQ rose... 
Via Benzinga
Topics Stocks
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
Malaysian Patent Granted for CytoMed Therapeutics' Licensed Allogeneic CAR-Gamma Delta T Cell Technology
The Company now has exclusive rights to a Malaysia, US and China patent 
From CYTOMED THERAPEUTICS LIMITED
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
 
Via Benzinga
Singapore’s Journey to Becoming a Biotech Powerhouse
Singapore's Biotech Vision: From 2000 Onwards In 2000, Singapore embarked on an ambitious mission to establish itself as a leading 
Via Spotlight Growth
Topics Economy
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.